Home World News Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus... World News Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 888 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR High-Fat Diet or Diabetes Drug May Enhance Response to Targeted Cancer... August 8, 2018 Few People with Cancer Undergo Testing for Inherited Gene Mutations August 1, 2023 Three cancer drugs approved for NHS use in Scotland November 11, 2021 The most important cancer research stories of 2022 December 14, 2022 Load more HOT NEWS Potential for Larger Gene Panels to Increase the Number of Molecularly... First-Line Pembrolizumab Continues to Show Durable Clinical Benefit After 5 Years... Remembering With Gratitude Qué debo saber sobre la mastectomía con cierre plano después de...
